Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?

3 Answers

Mednet Member

Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center

I agree with @Dr. First Last's excellent take on CARTITUDE-4 and KarMMA-3. For patients who have had 2 prior lines of therapy, I am absolutely going to reach for CAR-T (or bispecific antibodies as their earlier-line studies get published) with an emphasis on cilta-cel based on the data at hand.

But w...

Mednet Member

Medical Oncology · University of Chicago

I have different answers for these different studies.

The short answer is "yes, most definitely" for cilta-cel based on CARTITUDE-4 and "probably not" for ide-cel.

Let's unpack it:

CARTITUDE-1 was a phase 2 trial of cilta-cel in heavily pretreated relapsed/refractory MM, which now shows a median PFS o...

Mednet Member

Medical Oncology · Memorial Sloan Kettering Cancer Center

Cilta-cel data appears far better than Ide-cel - we will see a shift in the use of the former product preferentially by many centers once the label changes. However, capacity at TCT centers will remain a rate-limiting step (only so many apheresis slots, staff, beds, etc., at each center) and will no...